Publications by authors named "Eriko Satomi"

Purpose: There are no methods for assessing the need for multimodal care in cancer cachexia. We examined nine components in evaluating needs among advanced cancer patients.

Methods: This was a self-administered survey.

View Article and Find Full Text PDF

Background: Palliative care for cancer helps improve and maintain patients' quality of life (QOL). Clinically meaningful changes in QOL measures are helpful when considering how a patient would want to spend the final days of their life. This study aimed to estimate the minimally important differences (MIDs) for within-person change for the European Organisation for Research and Treatment of Cancer QOL Questionnaire Core 15 Palliative Care (EORTC QLQ-C15-PAL) domains in advanced cancer patients in palliative care.

View Article and Find Full Text PDF

Purpose: To standardize and improve the safety and efficacy of opioid conversion in people with cancer.

Methods: The Multinational Association of Supportive Care in Cancer (MASCC), American Society of Clinical Oncology (ASCO), American Academy of Hospice and Palliative Medicine (AAHPM), Hospice and Palliative Nurses Association (HPNA), and Network Italiano Cure di Supporto in Oncologia (NICSO) convened an Expert Panel to develop recommendations based on a systematic review of the literature and a formal consensus process. The systematic review focused on randomized and non-randomized studies published from database inception to June 2022.

View Article and Find Full Text PDF

Background: Serum C-reactive protein (CRP) levels are correlated with patient outcomes in cancer. This study aimed to determine associations between the CRP level and the dietary intake, symptoms, and eating-related distress (ERD).

Methods: We conducted a multicenter survey among advanced cancer patients.

View Article and Find Full Text PDF

Background: Because of the limitations of pharmacological therapy, nonpharmacological therapies including intervention procedures are also important for quality of cancer pain management.

Objective: To clarify the availability of, number performed, barriers to performing, and educational practices of four interventional procedures (celiac plexus neurolysis/splanchnic nerve neurolysis, phenol saddle block, epidural analgesia, and intrathecal analgesia) in designated cancer hospitals.

Design: Cross-sectional survey.

View Article and Find Full Text PDF
Article Synopsis
  • Olanzapine is an atypical antipsychotic that helps prevent nausea and vomiting, particularly after highly emetogenic chemotherapy (HEC), but it can cause side effects like hyperglycemia and drowsiness.
  • A systematic review and meta-analysis assessed the effectiveness of olanzapine combined with standard triplet antiemetic therapy compared to triplet therapy alone, focusing on outcomes like nausea control and adverse effects.
  • Results showed that adding olanzapine significantly improved nausea and vomiting prevention in both acute and delayed phases with minimal adverse effects, indicating it can be beneficial for patients undergoing HEC.
View Article and Find Full Text PDF

Background: We aimed to examine the effectiveness of a nurse-led, screening-triggered early specialized palliative care intervention program for patients with advanced lung cancer.

Methods: Patients with advanced lung cancer who underwent initial chemotherapy were randomized to intervention and usual care groups between January 2017 and September 2019. The intervention comprised comprehensive needs assessments, counseling, and service coordination by advanced-level nurses.

View Article and Find Full Text PDF
Article Synopsis
  • Research lacks a standardized multi-day antiemetic regimen for chemotherapy, making it difficult to assess efficacy and safety.
  • A comprehensive search revealed no direct comparisons between multi-day and single-day antiemetic regimens, with variations in study quality and treatment protocols hindering robust analysis.
  • Preliminary findings indicate that three-drug combination therapies, particularly using aprepitant, may outperform two-drug regimens; further research is needed to better define antiemetic approaches for multi-day chemotherapy.
View Article and Find Full Text PDF

Pharmacists' roles in cachexia care are unclear. This study aimed to clarify the knowledge and practice of cachexia care and identify factors related to the practice of cachexia care among pharmacists. Information on the knowledge and practice of cachexia care was obtained.

View Article and Find Full Text PDF
Article Synopsis
  • Palonosetron is a second-generation anti-nausea drug that might be more effective than first-generation medications, and this study explores how dexamethasone (DEX) works with it during chemotherapy.
  • Researchers compared the effects of giving DEX for 1 day versus 3 days in preventing nausea and vomiting after moderately emetogenic chemotherapy (MEC), using data from studies published between 1990 and 2020.
  • The findings showed that while the 3-day DEX group had a higher rate of no vomiting, there were no major differences in most anti-nausea effects, suggesting that DEX treatment could be shortened to just 1 day when paired with palonosetron.
View Article and Find Full Text PDF
Article Synopsis
  • - The study focuses on the effectiveness and safety of dexamethasone-sparing antiemetic therapies, particularly neurokinin-1 antagonists (NKRA), for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC).
  • - A systematic review of literature identified and analyzed two studies involving anthracycline-cyclophosphamide and cisplatin-based regimens; while no significant differences in vomiting prevention were found, some outcomes related to nausea showed variability.
  • - The review concludes that dexamethasone-sparing antiemetic therapies can be effective in preventing CINV for HEC, particularly in patients receiving anthracycline-cyclophosphamide
View Article and Find Full Text PDF
Article Synopsis
  • Chemotherapy-induced nausea and vomiting (CINV) negatively impacts patient quality of life, leading to a study that evaluated the effectiveness of adding neurokinin-1 receptor antagonists (NK1RAs) to existing antiemetic treatments for patients undergoing moderately emetogenic chemotherapy (MEC).
  • A systematic review of clinical studies identified 15 randomized controlled trials involving over 4,400 patients, revealing that triplet antiemetic regimens including NK1RAs significantly improved complete response and complete control of nausea compared to doublet regimens, without increasing adverse events.
  • While the addition of NK1RA shows promise for enhancing antiemetic efficacy in carboplatin-based chemotherapy, further research is needed
View Article and Find Full Text PDF

Introduction: Malignant wounds are lesions caused by metastasis from distant primary cancers or by direct invasion of the cutaneous structures of a primary cancer, and are most common in patients with breast or head and neck cancers. Malignant wounds not only cause physical symptoms, but also affect survival. Recognizing prognosis in terminal-stage cancer patients is necessary for both patients and health care providers.

View Article and Find Full Text PDF

Purpose: Myofascial pain syndrome (MPS) is a chronic musculoskeletal pain syndrome. The purpose of this review is to describe the epidemiological and treatment evidence and to address the future research agenda in patients with cancer.

Methods: A narrative review of previous reports investigating the prevalence and treatment of MPS in the oncology field is presented.

View Article and Find Full Text PDF

Background: Clinicians regularly prescribe opioids to manage acute and chronic cancer pain, frequently to address acute postoperative pain, and occasionally to manage chronic non-cancer pain. Clinical efficacy may be suboptimal in some patients due to side effects and/or poor response, and opioid rotation/switching (conversions) is frequently necessary. Despite the widespread practice, opioid conversion ratios are inconsistent between clinicians, practices, and countries.

View Article and Find Full Text PDF

Purpose: In this study, we aimed to evaluate the safety and effectiveness of naldemedine for treating opioid-induced constipation (OIC) in patients with advanced cancer, who are receiving palliative care, and particularly explored its early effects.

Methods: Palliative care teams and inpatient palliative care units across 14 institutions in Japan were included in this multicenter, prospective, observational study. Patients who were newly prescribed a daily oral dose of 0.

View Article and Find Full Text PDF
Article Synopsis
  • - The Japan Society of Clinical Oncology updated its 2023 Clinical Practice Guidelines for Antiemesis to incorporate recent findings on antiemetics and cancer treatments, reflecting the latest advancements in the field
  • - A thorough literature search from 1990 to 2020 was conducted to guide the update, leading to the development of 13 background questions, 12 clinical questions, and three future research questions
  • - The updated guidelines aim to enhance understanding and decision-making about antiemetic therapy for both patients and healthcare providers
View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness of non-drug therapies for managing anticipatory chemotherapy-induced nausea and vomiting (CINV) in cancer patients, focusing on the impact of past chemotherapy experiences.
  • Out of 107 studies reviewed, six were suitable for inclusion, highlighting three key non-pharmacologic treatments: systematic desensitization, hypnotherapy, and yoga therapy; systematic desensitization showed significant positive results in reducing nausea and vomiting.
  • Despite promising findings for systematic desensitization, concerns about study quality and inconsistent reporting of side effects indicate a need for more rigorous research before these methods are widely adopted in clinical practice.
View Article and Find Full Text PDF
Article Synopsis
  • * Data from 232 RDs was analyzed, revealing significant differences in areas like training, use of clinical guidelines, assessment methods, and overall confidence related to cancer cachexia.
  • * Key findings showed that RDs' knowledge, confidence, and the number of symptoms they used in assessments were critical factors impacting their multimodal care practices.
View Article and Find Full Text PDF

Introduction: In opioid therapy for cancer pain, opioid-induced nausea and vomiting (OINV) occur in 20%-40% of patients during initial opioid treatment or increasing opioid doses. OINV result in failure to achieve pain relief due to poor opioid adherence. Therefore, antiemetics are used to prevent OINV, but their efficacy and safety in this context have not yet been fully elucidated.

View Article and Find Full Text PDF

Context: Antipsychotics are often used in managing symptoms of terminal delirium, but evidence is limited.

Objectives: To explore the comparative effectiveness of haloperidol with as-needed benzodiazepines (HPD) vs. chlorpromazine (CPZ) vs.

View Article and Find Full Text PDF